Silexion (NASDAQ: SLXN) plans 1-for-10 reverse share split to aid Nasdaq compliance
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Silexion Therapeutics Corp is implementing a 1-for-10 reverse share split of its ordinary shares. The split becomes effective after market close on May 28, 2026, with shares trading on a reverse split-adjusted basis on the Nasdaq Capital Market from May 29, 2026 under the symbol SLXN.
Every ten ordinary shares will be automatically combined into one share, and the par value will increase from $0.0135 to $0.135 per share. No fractional shares will be issued; eligible DTC participants will have any fractional entitlements rounded up to the nearest whole share. The company states that the reverse split is intended, among other things, to help maintain compliance with Nasdaq’s minimum bid price requirement and support its strategic plans as it advances its RNAi candidate SIL204 toward a Phase 2/3 trial in locally advanced pancreatic cancer.
Positive
- None.
Negative
- None.
Insights
Silexion consolidates shares 1-for-10 mainly to support Nasdaq bid price compliance.
Silexion is executing a 1-for-10 reverse share split, combining every ten ordinary shares into one and proportionately increasing par value to $0.135 per share. Trading on a split-adjusted basis begins on the Nasdaq Capital Market on May 29, 2026 with the SLXN ticker unchanged.
The company explicitly links this action to maintaining compliance with Nasdaq’s minimum bid price requirement under Listing Rule 5550(a)(2) and to supporting strategic growth and potential equity financings. A new CUSIP will identify the post-split shares, while shareholders in book-entry or brokerage form need take no action.
The split does not change Silexion’s aggregate market value by itself but reduces the share count and increases the per-share price mechanically. Future disclosures on financing activities and the planned Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer, expected to commence in Q2 2026, will clarify how this capital structure supports the development program.
8-K Event Classification
2 items: 8.01, 9.01
2 items
Item 8.01
Other Events
Other
Voluntary disclosure of events the company deems important to shareholders but not covered by other items.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Reverse split ratio: 1-for-10
Par value before split: $0.0135 per share
Par value after split: $0.135 per share
+3 more
6 metrics
Reverse split ratio
1-for-10
Every ten ordinary shares combined into one share
Par value before split
$0.0135 per share
Ordinary shares par value prior to reverse share split
Par value after split
$0.135 per share
Ordinary shares par value after reverse share split
Effective date
May 28, 2026
Reverse share split effective after market close
Split-adjusted trading start
May 29, 2026
SLXN begins trading on a reverse split-adjusted basis on Nasdaq
Nasdaq rule reference
Rule 5550(a)(2)
Minimum bid price requirement cited as a purpose of the split
Key Terms
reverse share split, Nasdaq Capital Market, RNA interference (RNAi), Phase 2/3 trial, +2 more
6 terms
Nasdaq Capital Market financial
"trading on a reverse split-adjusted basis on the Nasdaq Capital Market at the open"
The Nasdaq Capital Market is a platform where smaller, emerging companies can list their shares for trading by investors. It provides these companies with access to funding and visibility, helping them grow, much like a local marketplace where new vendors can introduce their products to potential customers. For investors, it offers opportunities to discover early-stage companies with growth potential.
RNA interference (RNAi) medical
"a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers"
A natural cellular process in which small RNA molecules shut down the production of a specific protein by blocking the instructions that make it, like flipping a precise light switch to silence one appliance without affecting others. For investors, RNA interference is important because it underpins a class of highly targeted therapies and research tools that can create new drugs, shorten development paths, and change the potential market and regulatory risks for companies working on gene-based treatments.
Phase 2/3 trial medical
"initiation of our Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer this quarter"
A phase 2/3 trial is a combined clinical study that first tests whether a treatment shows enough benefit and acceptable safety (phase 2) and then expands into a larger test to confirm those results and measure effectiveness more precisely (phase 3). Like moving from a small dress rehearsal to a full performance without stopping between, it can speed development and lower costs, and investors watch results closely because strong outcomes can greatly reduce regulatory risk and shorten the timeline to market, while failures can sharply lower a drug’s value.
minimum bid price requirement regulatory
"intended, among other things, to enable the Company to maintain compliance with Nasdaq’s minimum bid price requirement"
A minimum bid price requirement is a rule that a stock must trade above a set price for a specified period to stay listed on an exchange. It matters to investors because falling below that threshold can trigger warnings or removal from the exchange, which can cut liquidity, reduce visibility, and often lead to sharper declines in share value—think of it like a venue’s minimum dress code that, if not met, can bar a performer from the stage.
KRAS oncogene medical
"solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic"
KRAS oncogene is a gene that, when mutated, can drive cells to grow uncontrollably and form tumors; think of it as a car’s accelerator stuck in the “on” position. Investors care because KRAS mutations create clear targets for drugs, diagnostics, and clinical trials, shaping the market value of therapies and diagnostics, regulatory outcomes, and the outlook for companies developing treatments that can block or detect these mutations.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
|
(State or other jurisdiction
|
|
(Commission File Number)
|
|
(I.R.S. Employer
|
|
of incorporation)
|
|
|
Identification No.)
|
|
|
|
|
|
(Address of principal executive offices)
|
|
(Zip Code)
|
-3-756-4999
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class
|
|
Trading Symbol(s)
|
|
Name of each exchange on which registered
|
|
|
|
|||
|
|
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with
any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 8.01 Other Events.
Further to its previous reports, as well as the approval of its shareholders received on May 5, 2026, on May 26,
2026, Silexion Therapeutics Corp, a Cayman Islands exempted company (“Silexion” or the “Company”) issued a press release announcing a prospective 1-for-10 reverse share split of all of its issued and outstanding, and authorized but unissued, ordinary shares. The reverse share split will
become effective after the close of the market on May 28, 2026, and the Company’s ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at the open of the market on May 29, 2026. The ticker symbol for the
ordinary shares will remain “SLXN.”
The reverse share split will be effected automatically, without any action required on the part of the Company’s
shareholders. The reverse share split will result in a corresponding increase in the par value of the Company’s ordinary shares, from $0.0135 per share to $0.135 per share. No fractional shares will be issued as a result of the reverse share split,
as any fractional share totals as to which shareholders who are DTC participants become entitled will be rounded up to the nearest whole number of shares. A copy of the press release announcing the reverse share split is attached as Exhibit 99.1 to
this report and is incorporated herein by reference.
Item 9.01 Financial Statements and Exhibits
(d) Exhibits
|
99.1
|
Press Release dated
May 26, 2026
|
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be
signed on its behalf by the undersigned hereunto duly authorized.
|
|
SILEXION THERAPEUTICS CORP
|
|
|
|
|
|
|
Date: May 26, 2026
|
By:
|
/s/ Ilan Hadar
|
|
|
Name:
|
Ilan Hadar
|
|
|
Title:
|
Chief Executive Officer
|
Exhibit 99.1
Silexion Therapeutics Announces 1-for-10 Reverse Share Split
Trading on split-adjusted basis will begin at market open on May 29, 2026. This
adjustment is expected to help Silexion comply with Nasdaq requirements, enhance its market
position, and support its progress in developing SIL-204
GRAND CAYMAN, Cayman Islands, May 26,
2026 - Silexion Therapeutics Corp. (NASDAQ: SLXN) (“Silexion” or the “Company”), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced a 1-for-10 reverse share split of
its ordinary shares. The reverse share split will become effective after market close on May 28, 2026, and the Company’s ordinary shares will begin trading on a reverse split-adjusted basis on the Nasdaq Capital Market at market open on May 29,
2026, under the existing ticker symbol “SLXN.” A new CUSIP number will be assigned to the post-reverse split shares.
As a result of the reverse share split, every ten ordinary shares of Silexion issued and outstanding will be automatically combined into
one share. The par value of the ordinary shares will be proportionately increased, from $0.0135 per share to $0.135 per share, and no fractional shares will be issued. Shareholders that are direct participants in the DTC system and that are
entitled to fractional shares will each receive a rounded-up whole share.
“This reverse share split is a deliberate step to preserve our Nasdaq listing and reinforce the capital structure that supports
Silexion's clinical execution,” said Ilan Hadar, Chairman and CEO of Silexion. “As we approach the initiation of our Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer this quarter, we want to enter that next phase from a position of
strength in the public markets. We believe a higher per-share trading range will help reduce volatility, broaden the universe of investors able to engage with our story, and improve our flexibility to fund the continued advancement of SIL204 toward
patients with KRAS-driven cancers who have few options today.”
Shareholders holding shares in book-entry form do not need to take any action in respect of the reverse share split, as their shares will
be adjusted automatically. Those holding shares through a broker or nominee will also not need to take any action, as the number of shares held by them will be adjusted automatically, as reflected in their brokerage account. For further details,
those shareholders should contact their broker.
The reverse share split is intended, among other things, to enable the Company to maintain compliance with Nasdaq’s minimum bid price
requirement, as outlined in Nasdaq Listing Rule 5550(a)(2). This adjustment is expected to help Silexion align with Nasdaq standards, enhance its market position, and support its strategic growth initiatives (including by enabling the Company to
conduct equity financings).
About Silexion Therapeutics
Silexion Therapeutics is a pioneering clinical-stage, oncology-focused biotechnology company dedicated to the development of innovative
treatments for unsatisfactorily treated solid tumor cancers which have the mutated KRAS oncogene, generally considered to be the most common oncogenic gene driver in human cancers. The Company conducted a Phase 2a clinical trial in its
first-generation product, which showed a positive trend in comparison to the control of chemotherapy alone, and is currently advancing its lead, second-generation, product candidate, SIL204, a small interfering RNA (siRNA), towards clinical trials
in Israel and the European Union. Silexion is committed to pushing the boundaries of therapeutic advancements in the field of oncology, and further developing its lead product candidate for locally advanced pancreatic cancer. For more information
please visit: https://silexion.com
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the federal securities laws. All statements other than
statements of historical fact contained in this communication are forward-looking statements, including, for example, statements regarding: the development of SIL204; the timing, design, conduct, and initiation of the planned Phase 2/3 clinical
trial of SIL204 in locally advanced pancreatic cancer (including the expected commencement in the second quarter of 2026); the Company’s anticipated future financing activities; the Company’s planned reverse share split and the timing of its
effectiveness; the Company’s restoration and future maintenance of compliance with the continued listing requirements of the Nasdaq Capital Market; the potential therapeutic benefits and clinical utility of SIL204; Silexion’s business strategy and
development plans; and Silexion’s future capital requirements and ability to raise additional capital. These forward-looking statements are generally identified by terminology such as “may”, “should”, “could”, “might”, “plan”, “possible”, “expect”,
“intend”, “will”, “estimate”, “anticipate”, “believe”, “prospective”, “potential” or “continue”, or the negatives of these terms or variations of them, or similar terminology. Forward-looking statements involve a number of risks, uncertainties, and
assumptions, and actual results or events may differ materially from those projected or implied in those statements. Important factors that could cause such differences include, but are not limited to: (i) whether Silexion will succeed at
initiating and conducting clinical trials, including the Phase 2/3 trial of SIL204 in locally advanced pancreatic cancer; (ii) whether Silexion’s strategy, future operations, financial position, projected costs, prospects, and plans will run as
currently anticipated; (iii) the impact of the regulatory environment and compliance complexities; (iv) whether Silexion can establish future partnerships or other relationships with third parties; (v) Silexion’s future capital requirements and
sources and uses of cash, including its ability to obtain additional capital; (vi) whether Silexion can maintain its Nasdaq listing, including its ability to continue to satisfy the Nasdaq minimum bid price requirement; and (vii) other risks and
uncertainties set forth in the documents filed by the Company with the SEC, including the Company’s Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 17, 2026, and the Company’s Quarterly Report on Form
10-Q for the quarter ended March 31, 2026, filed with the SEC on May 15, 2026. Silexion cautions you against placing undue reliance on forward-looking statements, which reflect current beliefs and are based on information currently available as of
the date a forward-looking statement is made. Forward-looking statements set forth herein speak only as of the date they are made. Silexion undertakes no obligation to revise forward-looking statements to reflect future events, changes in
circumstances, or changes in beliefs, except as otherwise required by law.
Company Contact
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Capital Markets & IR Contact
Arx Capital Markets
North American Equities Desk
silexion@arxhq.com
Silexion Therapeutics Corp
Ms. Mirit Horenshtein Hadar, CFO
mirit@silexion.com
Capital Markets & IR Contact
Arx Capital Markets
North American Equities Desk
silexion@arxhq.com
FAQ
What did Silexion Therapeutics (SLXN) announce in its latest 8-K?
Silexion announced a 1-for-10 reverse share split of its ordinary shares. The split becomes effective after market close on May 28, 2026, with split-adjusted trading on Nasdaq beginning May 29, 2026, under the unchanged ticker SLXN.
When will Silexion (SLXN) start trading on a split-adjusted basis?
Silexion’s ordinary shares will begin trading on a reverse split-adjusted basis on May 29, 2026. The reverse share split becomes effective after the market closes on May 28, 2026, and the company’s Nasdaq Capital Market ticker will remain SLXN.
How does the reverse split relate to Silexion’s SIL204 development plans?
Silexion links the reverse split to reinforcing its capital structure as it advances SIL204. The company is approaching initiation of a Phase 2/3 trial in locally advanced pancreatic cancer and indicates that maintaining Nasdaq compliance and financing flexibility supports continued development of this RNAi candidate.